{"ModuleTitle": "Company Description", "CompanyName": "Esperion Therapeutics, Inc.", "Symbol": "ESPR", "Address": "3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, Michigan, 48108, United States of America", "Phone": "734-887-3903", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are the Lipid Management Company, a pharmaceutical company focused on\r\ndeveloping and commercializing affordable, oral, once-daily, non-statin\r\nmedicines for the treatment of patients with elevated low density lipoprotein\r\ncholesterol, or LDL-C. Through scientific and clinical excellence, and a deep\r\nunderstanding of cholesterol biology, the experienced Lipid Management Team at\r\nEsperion is committed to developing new LDL-C lowering medicines that will make\r\na substantial impact on reducing global cardiovascular disease, or CVD; the\r\nleading cause of death around the world. NEXLETOLTM (bempedoic acid) tablet and\r\nNEXLIZETTM (bempedoic acid and ezetimibe) tablets are the first, oral,\r\nonce-daily, non-statin LDL-C lowering medicines approved in the U.S. in nearly\r\n20 years for patients with atherosclerotic cardiovascular disease, or ASCVD, or\r\nheterozygous familial hypercholesterolemia, or HeFH.\r\n\r\nOn February 21, 2020, we announced that the U.S.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f27%2f0001104659-20-026203.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Ken Fiorelli", "title": "Chief Technical Operations Officer"}, {"name": "Richard B. Bartram", "title": "Chief Financial Officer & Secretary"}, {"name": "Tim M. Mayleben", "title": "President, Chief Executive Officer & Director"}, {"name": "William J. Sasiela", "title": "Senior Vice President-Clinical Development"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}